Eurand (Milan, Italy) Announces NDA Filing by GlaxoSmithKline for Co-development Product

PHILADELPHIA, Dec. 18, 2007 (PRIME NEWSWIRE) -- Eurand N.V. (Nasdaq:EURX), a specialty pharmaceutical company that develops enhanced pharmaceutical and biopharmaceutical products based on its proprietary drug formulation technologies, announced today that GlaxoSmithKline ("GSK") has filed a New Drug Application (NDA) with the Food and Drug Administration (FDA) for an orally disintegrating tablet formulation of a product co-developed with Eurand using the Company's Microcaps(r) taste-masking and AdvaTab(r) technologies.